Palentis
Healthcare strategy and business development consulting for investors and companies in medical devices, pharma, drug delivery and cosmetics
Highlights
- New on EvolcAdded 2026-11-14
About Palentis
Palentis advises healthcare industry players on strategy, business development and M&A. Services include strategic planning, P&L shaping, licensing, market access, due diligence and negotiation support.
Its clients include healthcare investors and companies across medical devices, pharmaceuticals, drug delivery and cosmetics. The company is based in Saint-Martin-D'Hères, France, and was founded in 2016.
Product: Strategic planning, business development and M&A advisory for healthcare industry players.
Jobs at Palentis
More consulting & professional services companies
Paleotime
Preventive archaeology excavations and studies for developers and public infrastructure projects in FrancePali Kao Capital
Wealth management and investment advice for individuals and businesses in ParisNew on EvolcPalmer Consulting
Management consulting and expert staffing for finance, transformation, data and customer experience teamsPALO IT
Technology consulting and digital product engineering for enterprises across APAC, Europe and the AmericasRemote-friendlyPanacee Expertise
Accounting and tax advisory services for medical and paramedical professionals in France and the French overseas territoriesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Frontend frameworks
- AstroMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- VueMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.